Patient P-02381

Synthetic patientMETA-24 · Day 122 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Favorable

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 66 SC-12 recommended — Supportive Compound SC-12
Day 67 Patient accepted — Started SC-12 in the companion
Day 73 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 74 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 78 GI-04 recommended — GI Support Protocol GI-04
Day 79 Patient accepted — Started GI-04 in the companion
Day 79 Tolerance state changed — Unstable → Improving
Day 87 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 74.

Primary contributors, last 14 days

Treatment adherence-12
GI instability-8
Toxicity-4

What helped?

Supportive Compound SC-12Day 66
Result: symptom burden −17%
GI Support Protocol GI-04Day 78
Result: no meaningful change

LIFE OS recommendation

Monitoring Escalation ME-01

75%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

25 min

worsening · -5.6 vs previous 14 d

Sleep duration

Wearable

5.9 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

3.3/10

worsening · -0.3 vs previous 14 d

Steps

Wearable

2,661

worsening · -426 vs previous 14 d

GI burden

Companion

57.9/100

stable · +2.1 vs previous 14 d

Adherence

Companion

51 %

worsening · -18.3 vs previous 14 d

Sleep quality

Wearable

10.1/100

worsening · -3.1 vs previous 14 d

Glucose, CGM daily mean

CGM

147 mg/dL

stable · +0.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 34 from the failing basin, 57 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 63%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 63%
CR-01 Clinician Review
100% improved among 7 similar · onset 5 d · confidence 63%
More protein
GI -3.3 next day on high-intake days · n 14

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep caffeine low
GI +3.9 next day on high-intake days · n 23
Keep fat low
GI +3.4 next day on high-intake days · n 17
Keep alcohol low
GI +2.7 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Caffeine
+3.9detractor · 95%
Dietary fat load
+3.4detractor · 95%
Protein
-3.3supporter · 95%
Alcohol
+2.7detractor · 74%
Ultra-processed food
+2.5detractor · 77%
Simple carbohydrates
+2.2detractor · 67%
Insoluble fibre
+2.1detractor · 56%
Histamine load
+2detractor · 68%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 58 and rising
- WearableSleep 5.9 h, below personal baseline
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
- WearableHRV 18 ms, trending down
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
Autonomic recovery ↑40
- Wearable2,661 steps/day
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.6 · butyrate capacity 48/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 17 ms
Sleep: 5.9 h
Steps: 2,640
Resting HR: 66 bpm

Daily log: GI score 58, nutritional resilience 38, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02409	42%	S01	SC-12	no change	54
P-02018	35%	S01	GI-04	improved	46
P-02410	33%	S01	GI-04	improved	55
P-02054	31%	S01	CR-01	improved	57
P-02307	23%	S01	—	—	55
P-02598	23%	S01	—	—	53
P-02276	21%	S01	—	—	57
P-02550	21%	S01	—	—	70
P-02568	21%	S01	—	—	51
P-02041	20%	S01	—	—	27
P-02087	20%	S01	BR-03	no change	40
P-02138	20%	S01	—	—	79